GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Abivax SA American Depositary Shares ABVX · USD

Health Care · US listing · 🇺🇸 United States

Compare

87.00

+1.48%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Abivax SA American Depositary Shares

Its shares trade under the ticker ABVX. It has been listed since 20 October 2023. In the fiscal year to 31 December 2024, it reported revenue of $12.3m and a net loss of $200.9m. At that date it held total assets of $233.9m and shareholders' equity of $46.3m.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
20 Oct 2023
Employees
69
Website
abivax.com ↗
Head office
7 BD HAUSSMANN, PARIS
Incorporated in
I0
Classification
Pharmaceutical Preparations
Filer status
Accelerated filer<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Abivax SA has 69 employees focused on clinical-stage biotechnology development.
  • Obefazimod is in Phase 3 clinical trials for ulcerative colitis treatment.
  • The company's lead drug candidate targets chronic inflammatory diseases with natural immune stabilization.

Weaknesses

  • Abivax SA was listed on the stock market on 20 October 2023.
  • The company has only one lead drug candidate, obefazimod, in development.
  • Abivax SA is a clinical-stage biotechnology company with no approved products yet.

Opportunities

  • Abivax SA is developing obefazimod for Phase 2b trials in Crohn's disease treatment.
  • The company's focus on immune response stabilization offers potential for new therapeutic applications.
  • Abivax SA's clinical-stage development could attract future partnerships in the Health Care sector.

Threats

  • Abivax SA faces competition from other biotechnology companies in the Health Care sector.
  • The company's reliance on a single drug candidate, obefazimod, poses development risks.
  • Clinical trials for obefazimod could face delays or failures in the Health Care industry.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.